L-Carnitine is a naturally-occurring quaternary ammonium compound derived from the amino acids lysine and methionine, with a well-defined biochemical role in fatty-acid transport across the mitochondrial membrane. The injectable form (levocarnitine) is FDA-approved for primary and secondary carnitine deficiency and is supplied as a pharmaceutical-grade preparation alongside research-grade vial offerings. This monograph lays out the chemistry, the mitochondrial fatty-acid-transport mechanism, the registered indications, and the considerations specific to injectable carnitine in research contexts.
Chemical identity and structure.
L-Carnitine is (3R)-3-hydroxy-4-(trimethylammonio)butanoate, molecular formula C₇H₁₅NO₃, molecular weight 161.2 g/mol. Only the L-isomer is biologically active in mammalian systems; the D-isomer is inert and has been associated with adverse effects in clinical contexts where racemic mixtures were once used. The compound is highly water-soluble, hygroscopic in solid form, and stable as a sterile injectable solution. The FDA-approved injectable formulation (levocarnitine) is registered as Carnitor and equivalents.
Mechanism of action.
L-Carnitine's central biochemical role is in the carnitine palmitoyltransferase (CPT) shuttle, by which long-chain fatty acids are transported across the inner mitochondrial membrane for β-oxidation. Cytosolic fatty-acyl-CoA is conjugated to carnitine (CPT-I), the resulting acylcarnitine crosses the membrane via the carnitine/acylcarnitine translocase, and matrix carnitine is regenerated as the acyl group is transferred to mitochondrial CoA (CPT-II). Carnitine deficiency disrupts long-chain fatty-acid β-oxidation, producing the characteristic clinical syndrome of skeletal-muscle weakness, cardiomyopathy, and hypoketotic hypoglycaemia.
Research applications and the evidence base.
Injectable L-carnitine has FDA-approved indications for primary and secondary systemic carnitine deficiency, including the carnitine deficiency that accompanies end-stage renal disease on hemodialysis. Published clinical literature includes controlled trials in metabolic carnitine-transporter disorders, hemodialysis-associated carnitine depletion, valproic-acid hepatotoxicity, and cardiomyopathy associated with carnitine deficiency. Research applications outside the registered indications include cardiac-bioenergetics research, fatty-acid-oxidation biochemistry, and exercise-physiology questions.
Research context.
L-Carnitine is the canonical CPT-shuttle cofactor and the reference compound for any research question that touches mitochondrial long-chain fatty-acid β-oxidation. Researchers in fatty-acid-metabolism models use it as the defined rescue agent in carnitine-depleted systems.
Storage and handling.
Pharmaceutical-grade injectable L-carnitine solutions are stable at room temperature for the labelled shelf life and should be refrigerated after opening per the manufacturer's package insert. The solid form is hygroscopic and should be kept dry and away from light.
Quality and COA considerations.
A meaningful COA should confirm identity (NMR or HPLC against an authentic L-carnitine reference standard), purity by HPLC (≥99% benchmark), explicit L-isomer purity — racemic mixtures or D-isomer contamination is clinically meaningful, and sterility and endotoxin testing for any solution intended for injection-model use.
Research-use note: This monograph is an educational summary of the published research literature on injectable L-Carnitine. The injectable form has FDA-approved indications for carnitine-deficiency syndromes; use outside those indications remains research-grade. Nothing here is medical advice or a usage recommendation.
